Skip to content

Learn more about full-time, contractual, and consultant roles with Solve here.

  • RESOURCES:      
  • For Patients/Caregivers
  • For Medical Providers
  • For Researchers
solve-me-logo-color
Contact Us
Donate
  • ME/CFS + Long Covid
      • What is ME/CFS?
      • What is Long Covid?
      • Quiz: Do I Have ME/CFS?
      • Quiz: Do I Have Long Covid?
      • Long Covid Initiative
      • Long Haul Voices
      • Patient/Caregiver Resources
      • Medical Provider Resources
  • Research + Registry
      • Ramsay Research Grants
      • Meet the Researchers
      • Applying for a Grant
      • The You + ME Registry
  • Advocacy
      • Annual Advocacy Events
      • Advocacy Week 2023
      • EmPOWER M.E.
      • Advocacy Cafe Chats
      • Tools + Resources
      • Take Action Now
      • Statements + Letters
      • Humans of Chronic Illness
  • Donate + Engage
      • Solve Long Covid NOW
      • Donate Today
      • Other Ways To Give
  • News + Insights
      • Research 1st
      • The Chronicle
      • Press Releases
      • Alerts + Blog Posts
      • Media Kit + Solve M.E. in the News
      • Webinars
      • Events
      • Subscribe to Our Newsletter
  • About Us
      • Our Board
      • Our Staff
      • Our Research Advisory Council (RAC)
      • Lived Experience Taskforce (LET)
      • Our Partners
      • Solve M.E. Financials
      • Contact Us
      • Join Our Team

Learn more about full-time, contractual, and consultant roles with Solve here.

solve-me-logo-color

Day: September 21, 2022

Study Reveals First Genetic Links in ME/CFS, Could Accelerate Development of New Treatments

Oxford-based biotech company PrecisionLife announced that their combinatorial analysis of genetic data links 14 genes to ME/CFS and identifies many patient subgroups. According to a press release, “This is the […]

solve-me-logo-ko
thumbnail_Solve_Long_Covid_Initiative_logo_white

Making Breakthroughs Possible

Facebook Twitter Instagram Youtube Linkedin

Solve ME/CFS Initiative

350 N Glendale Ave.
Suite B #368
Glendale, CA 91206

SolveCFS@SolveCFS.org
704-364-0016

Explore

About Solve M.E.
Solve Long Covid NOW
Long Covid Initiative
What is ME/CFS?
What is Long Covid?
Advocacy Center
You + ME Registry
Research Grants

Donate

Ways to Give
Monthly Giving
Gifts of Securities
Donate

Join our newsletter

Subscribe

Copyright © 2022 The Solve ME/CFS Initiative. All rights reserved.

Privacy Policy
Terms of Use
Accessibility Statement
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT

Delaware

Cumulative Cost to Jan 31, 2022: $1.3B
% of Population with Long Covid: 7.7%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 73,000
# of Individuals with Disabling Long Covid: 24,000

Arizona

Cumulative Cost to Jan 31, 2022: $9.8B
% of Population with Long Covid: 8%
% of Population with Disabling Long Covid: 2.7%
# of Individuals with Long Covid: 554,000
# of Individuals with Disabling Long Covid: 184,000

Idaho

Cumulative Cost to Jan 31, 2022: $2B
% of Population with Long Covid: 6.7%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 113,000
# of Individuals with Disabling Long Covid: 37,500

California

Cumulative Cost to Jan 31, 2022: $43B
% of Population with Long Covid: 6.3%
% of Population with Disabling Long Covid: 2.1%
# of Individuals with Long Covid: 2,470,000
# of Individuals with Disabling Long Covid: 817,000

Washington D.C.

Cumulative Cost to Jan 31, 2022: $700M
% of Population with Long Covid: 5.6%
% of Population with Disabling Long Covid: 1.9%
# of Individuals with Long Covid: 38,000
# of Individuals with Disabling Long Covid: 13,000

Illinois

Cumulative Cost to Jan 31, 2022: $16B
% of Population with Long Covid: 10%
% of Population with Disabling Long Covid: 4%
# of Individuals with Long Covid: 860,000
# of Individuals with Disabling Long Covid: 285,000

Connecticut

Cumulative Cost to Jan 31, 2022: $3.7B
% of Population with Long Covid: 5.7%
% of Population with Disabling Long Covid: 1.9%
# of Individuals with Long Covid: 205,000
# of Individuals with Disabling Long Covid: 68,000

New Jersey

Cumulative Cost to Jan 31, 2022: $11B
% of Population with Long Covid: 7%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 619,000
# of Individuals with Disabling Long Covid: 205,000

Georgia

Cumulative Cost to Jan 31, 2022: $12.6B
% of Population with Long Covid: 6.8%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 702,000
# of Individuals with Disabling Long Covid: 233,000

Wyoming

Cumulative Cost to Jan 31, 2022: $775M
% of Population with Long Covid: 7.5%
% of Population with Disabling Long Covid: 2.5%
# of Individuals with Long Covid: 43,500
# of Individuals with Disabling Long Covid: 14,500

Wisconsin

Cumulative Cost to Jan 31, 2022: $8.1B
% of Population with Long Covid: 7.8%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 450,000
# of Individuals with Disabling Long Covid: 150,000

West Virginia

Cumulative Cost to Jan 31, 2022: $2.3B
% of Population with Long Covid: 7.2%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 132,000
# of Individuals with Disabling Long Covid: 44,000

Washington

Cumulative Cost to Jan 31, 2022: $6.7B
% of Population with Long Covid: 5.4%
% of Population with Disabling Long Covid: 1.8%
# of Individuals with Long Covid: 394,000
# of Individuals with Disabling Long Covid: 130,000

Virginia

Cumulative Cost to Jan 31, 2022: $8.2B
% of Population with Long Covid: 5.4%
% of Population with Disabling Long Covid: 1.8%
# of Individuals with Long Covid: 457,000
# of Individuals with Disabling Long Covid: 151,000

Vermont

Cumulative Cost to Jan 31, 2022: $500M
% of Population with Long Covid: 4.5%
% of Population with Disabling Long Covid: 1.5%
# of Individuals with Long Covid: 28,000
# of Individuals with Disabling Long Covid: 9,000

Utah

Cumulative Cost to Jan 31, 2022: $4.7B
% of Population with Long Covid: 10%
% of Population with Disabling Long Covid: 4%
# of Individuals with Long Covid: 262,000
# of Individuals with Disabling Long Covid: 87,000

Texas

Cumulative Cost to Jan 31, 2022: $33B
% of Population with Long Covid: 6.6%
% of Population with Disabling Long Covid: 2%
# of Individuals with Long Covid: 1,840,000
# of Individuals with Disabling Long Covid: 611,000

Tennessee

Cumulative Cost to Jan 31, 2022: $9.9B
% of Population with Long Covid: 8.3%
% of Population with Disabling Long Covid: 2.8%
# of Individuals with Long Covid: 555,000
# of Individuals with Disabling Long Covid: 184,000

Oklahoma

Cumulative Cost to Jan 31, 2022: $5.1B
% of Population with Long Covid: 7.4%
% of Population with Disabling Long Covid: 2.5%
# of Individuals with Long Covid: 290,000
# of Individuals with Disabling Long Covid: 96,000

Oregon

Cumulative Cost to Jan 31, 2022: $3.3B
% of Population with Long Covid: 4.6%
% of Population with Disabling Long Covid: 1.5%
# of Individuals with Long Covid: 187,000
# of Individuals with Disabling Long Covid: 62,000

Pennsylvania

Cumulative Cost to Jan 31, 2022: $14B
% of Population with Long Covid: 6.1%
% of Population with Disabling Long Covid: 2%
# of Individuals with Long Covid: 783,000
# of Individuals with Disabling Long Covid: 260,000

Rhode Island

Cumulative Cost to Jan 31, 2022: $1.8B
% of Population with Long Covid: 9.5%
% of Population with Disabling Long Covid: 3.1%
# of Individuals with Long Covid: 100,000
# of Individuals with Disabling Long Covid: 33,000

South Carolina

Cumulative Cost to Jan 31, 2022: $7.2B
% of Population with Long Covid: 8.3%
% of Population with Disabling Long Covid: 2.7%
# of Individuals with Long Covid: 410,000
# of Individuals with Disabling Long Covid: 136,000

Ohio

Cumulative Cost to Jan 31, 2022: $14B
% of Population with Long Covid: 6.6%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 763,000
# of Individuals with Disabling Long Covid: 253,000

North Dakota

Cumulative Cost to Jan 31, 2022: $1.2B
% of Population with Long Covid: 8.8%
% of Population with Disabling Long Covid: 2.9%
# of Individuals with Long Covid: 66,500
# of Individuals with Disabling Long Covid: 22,000

North Carolina

Cumulative Cost to Jan 31, 2022: $12.6B
% of Population with Long Covid: 7.1%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 716,000
# of Individuals with Disabling Long Covid: 238,000

New York

Cumulative Cost to Jan 31, 2022: $17.5B
% of Population with Long Covid: 7.2%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 1,400,000
# of Individuals with Disabling Long Covid: 464,000

New Hampshire

Cumulative Cost to Jan 31, 2022: $1.5B
% of Population with Long Covid: 6.1%
% of Population with Disabling Long Covid: 2%
# of Individuals with Long Covid: 81,500
# of Individuals with Disabling Long Covid: 27,000

Nevada

Cumulative Cost to Jan 31, 2022: $3.5B
% of Population with Long Covid: 6.7%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 195,000
# of Individuals with Disabling Long Covid: 65,000

Nebraska

Cumulative Cost to Jan 31, 2022: $2.4B
% of Population with Long Covid: 6.9%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 131,000
# of Individuals with Disabling Long Covid: 43,500

Montana

Cumulative Cost to Jan 31, 2022: $1.3B
% of Population with Long Covid: 6.9%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 72,000
# of Individuals with Disabling Long Covid: 24,000

Missouri

Cumulative Cost to Jan 31, 2022: $7.1B
% of Population with Long Covid: 6.5%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 394,000
# of Individuals with Disabling Long Covid: 131,000

Mississippi

Cumulative Cost to Jan 31, 2022: $3.9B
% of Population with Long Covid: 7.2%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 216,000
# of Individuals with Disabling Long Covid: 72,000

Minnesota

Cumulative Cost to Jan 31, 2022: $7B
% of Population with Long Covid: 7.1%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 391,000
# of Individuals with Disabling Long Covid: 130,000

Michigan

Cumulative Cost to Jan 31, 2022: $12B
% of Population with Long Covid: 6.7%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 669,000
# of Individuals with Disabling Long Covid: 222,000

Massachusetts

Cumulative Cost to Jan 31, 2022: $8.6B
% of Population with Long Covid: 6.9%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 472,000
# of Individuals with Disabling Long Covid: 156,000

Arkansas

Cumulative Cost to Jan 31, 2022: $4.1B
% of Population with Long Covid: 7.7%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 230,000
# of Individuals with Disabling Long Covid: 76,500

Florida

Cumulative Cost to Jan 31, 2022: $30B
% of Population with Long Covid: 7.9%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 1,640,000
# of Individuals with Disabling Long Covid: 544,000

Colorado

Cumulative Cost to Jan 31, 2022: $6.7B
% of Population with Long Covid: 6.7%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 370,00
# of Individuals with Disabling Long Covid: 123,000

Hawaii

Cumulative Cost to Jan 31, 2022: $1.1B
% of Population with Long Covid: 4.4%
% of Population with Disabling Long Covid: 1.4%
# of Individuals with Long Covid: 62,000
# of Individuals with Disabling Long Covid: 20,500

Indiana

Cumulative Cost to Jan 31, 2022: $8.7B
% of Population with Long Covid: 7.3%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 481,100
# of Individuals with Disabling Long Covid: 160,000

Iowa

Cumulative Cost to Jan 31, 2022: $3.9B
% of Population with Long Covid: 6.8%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 214,000
# of Individuals with Disabling Long Covid: 71,000

Kansas

Cumulative Cost to Jan 31, 2022: $3.9B
% of Population with Long Covid: 7.4%
% of Population with Disabling Long Covid: 2.5%
# of Individuals with Long Covid: 216,000
# of Individuals with Disabling Long Covid: 72,000

Kentucky

Cumulative Cost to Jan 31, 2022: $6.1B
% of Population with Long Covid: 7.8%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 344,000
# of Individuals with Disabling Long Covid: 114,000

Louisiana

Cumulative Cost to Jan 31, 2022: $5.9B
% of Population with Long Covid: 7.1%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 330,000
# of Individuals with Disabling Long Covid: 110,000

Maine

Cumulative Cost to Jan 31, 2022: $940M
% of Population with Long Covid: 3.9%
% of Population with Disabling Long Covid: 1.3%
# of Individuals with Long Covid: 52,000
# of Individuals with Disabling Long Covid: 17,000

Maryland

Cumulative Cost to Jan 31, 2022: $5.2B
% of Population with Long Covid: 4.7%
% of Population with Disabling Long Covid: 1.6%
# of Individuals with Long Covid: 281,000
# of Individuals with Disabling Long Covid: 93,000

Alaska

Cumulative Cost to Jan 31, 2022: $1B
% of Population with Long Covid: 8.4%
% of Population with Disabling Long Covid: 2.8%
# of Individuals with Long Covid: 62,000
# of Individuals with Disabling Long Covid: 21,000

South Dakota

Cumulative Cost to Jan 31, 2022: $1.2B
% of Population with Long Covid: 7.8%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 67,000
# of Individuals with Disabling Long Covid: 22,100

Alabama

Cumulative Cost to Jan 31, 2022: $6.5B
% of Population with Long Covid: 7.5%
% of Population with Disabling Long Covid: 2.5%
# of Individuals with Long Covid: 363,000
# of Individuals with Disabling Long Covid: 121,000

New Mexico

Cumulative Cost to Jan 31, 2022: $2.5B
% of Population with Long Covid: 6.8%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 142,000
# of Individuals with Disabling Long Covid: 47,000
  • for patients / caregivers
  • for medical providers
  • for researchers
Donate
Contact Us
  • ME/CFS + Long Covid
    • What is ME/CFS?
    • What is Long Covid?
    • Do I Have ME/CFS? Quiz
    • Do I Have Long Covid? Quiz
    • Long Covid Initiative
    • Long Haul Voices
    • Patient and Caregiver Resources
    • Medical Providers Resources
  • Research + Registry
    • Ramsay Research Grants
    • Meet the Researchers
    • Applying for a Grant
    • The You + M.E. Registry
  • Advocacy
    • Annual Advocacy Events
    • Advocacy Week 2023
    • EmPOWER M.E.
    • Advocacy Cafe Chats
    • Tools & Resources
    • Take Action Now
    • Statements & Letters
    • Humans of Chronic Illness
  • Donate + Engage
    • Solve Long Covid NOW
    • Donate Today
    • Other Ways to Give
  • News + Insights
    • Research 1st
    • The Chronicle
    • Press Releases
    • Alerts + Blog Posts
    • Media Kit + Solve M.E. in the News
    • Webinars
    • Events
    • Subscribe to Our Newsletter
  • About Us
    • Board of Directors
    • Solve M.E. Staff
    • Research Advisory Council
    • Lived Experience Taskforce (LET)
    • Solve M.E. Partners
    • Solve M.E. Financials
    • Contact Us
    • Join Our Team
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset